Bullboard - Stock Discussion Forum Evome Medical Technologies Inc V.EVMT

Alternate Symbol(s): LNDZF

Healthcare Medical Devices

Evome Medical Technologies Inc. is an international medical device company, which is focused on human performance and rehabilitative solutions. The Company’s products include Biodex Rehab product, Damar Plastics product, Mio-Guard product, Simbex services, and SDP product. Its Biodex Rehab products include Isokinetic Systems, Gait Trainer, Body-Weight Supported Training, Cycles and Ergometers... see more

Add To Watchlist

Bullboard (TSXV:EVMT)

View:

Comment by Inobambinoon Aug 15, 2024 2:30pm

RE:RE:Evome/Biodex

Yes, good timing ! It sounds like they feel really good about Biodex and the opportunities to grow that business. It's nice to have some optimisim again !

Discussion

Comment by jer13leafson Aug 15, 2024 9:49am

RE:Evome/Biodex

Looks like it took only 12 hours to get your answer. LOL It seems like they are trying to accelerate growth for overall value and limit costs. I hope it translates to the stock price movement. Good ...more

Discussion

(0)
•••

Post by PressReleaseon Aug 15, 2024 7:30am

New Press Release - Evome Medical Technologies Reviews Highlights of Low-CapEx Revenue Growth Plan

Posts updated corporate presentation to website Reminder: Conference call to be held on August 19th to discuss Q2 2024 financial resultsSHIRLEY, N.Y., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) highlights its low-CapEx plan for...read article.

Comment by taylorsimms86on Aug 14, 2024 7:45pm

RE:RE:Evome/Biodex

Also everyone has to stop blaming Bruce Campbell for their own mistakes...he runs a fund and if you want not only his best ideas but also his exits then invest in his fund. The guy had a 10 year track ...more

103

Discussion

Comment by taylorsimms86on Aug 14, 2024 7:41pm

RE:Evome/Biodex

Correct, Biodex was always the main business and lots of runway for growth and white labeling products to sell in the distribution chain...was a different market 3 years ago and the new CEO has come ...more

Discussion

Post by Inobambinoon Aug 14, 2024 7:05pm

Evome/Biodex

So am I correct in understanding that the company made several acquisitions over the past few years, all of which were unprofitable with the exception of Biodex ? This is leading to them divesting ...more

398

Discussion

Comment by Trekkieon Aug 14, 2024 3:36pm

RE:RE:RE:RE:We have

So far Mike has been clear with his guidance and has done everything they said they would. I am confident in them selling the assets to pay down debt. They have done everything they said they would ...more

Discussion

Comment by jer13leafson Aug 14, 2024 1:33pm

RE:RE:RE:We have

Looked ok to me and glad there was not a drop off in trading price after. It seems the exact oposite for once. What do others think? Thanks and good luck All the best

Discussion

Comment by taylorsimms86on Aug 13, 2024 9:56am

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:We have

100% agree...and Mike is doing it...has already completed sales of 2 other assets and says these two will be sold...has re-tooled production and added new sales channels into Asia and the USVA

Discussion

Comment by subaru1on Aug 13, 2024 9:48am

RE:RE:RE:RE:RE:RE:RE:RE:RE:We have

Next two quarter are crucial for EVOME, BIODEX is the key so how big is this market 50 millions 100 millions if it is the case and they sell the non core asset and cut the debt we are in business for ...more

Discussion

Comment by taylorsimms86on Aug 13, 2024 9:36am

RE:RE:RE:RE:RE:RE:RE:RE:We have

yes...interest was high...plus add the depreciation and amortization which are non-cash items you end up with a big loss...need to sell the last two non core assets they have promised to wipe away ...more

Discussion

Comment by BigJakeon Aug 13, 2024 7:12am

RE:RE:RE:RE:RE:RE:RE:RE:We have

Yes I must confess not being a tax accountant in this case definitely makes it harder to understand what is going on here. Need to go back and compare previous quarters revenue numbers.

Discussion